Log in

NASDAQ:VPHM - Shire Viropharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:VPHM
CUSIP92824110
Phone+1-610-4587300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive VPHM News and Ratings via Email

Sign-up to receive the latest news and ratings for VPHM and its competitors with MarketBeat's FREE daily newsletter.


Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions

What is Shire Viropharma's stock symbol?

Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."

Has Shire Viropharma been receiving favorable news coverage?

Media stories about VPHM stock have trended very negative on Sunday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shire Viropharma earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Shire Viropharma.

Who are some of Shire Viropharma's key competitors?

What other stocks do shareholders of Shire Viropharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire Viropharma investors own include Pharmacyclics (PCYC), Caterpillar (CAT), Johnson & Johnson (JNJ), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Costco Wholesale (COST), Gilead Sciences (Gild), Incyte (INCY), Medivation (MDVN) and Netflix (NFLX).

What is Shire Viropharma's official website?

The official website for Shire Viropharma is http://www.viropharma.com/.

How can I contact Shire Viropharma?

Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.


MarketBeat Community Rating for Shire Viropharma (NASDAQ VPHM)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  415 (Vote Underperform)
Total Votes:  676
MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe VPHM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VPHM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel